CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
氯法拉滨用于 CAR-T 细胞输注前淋巴细胞清除：简要病例报告
英文原题：Clofarabine for Lymphodepletion Before CAR-T-Cell Infusion: A Brief Case Report.
查看英文原题
Clofarabine for Lymphodepletion Before CAR-T-Cell Infusion: A Brief Case Report.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
氟达拉滨短缺使CAR-T 治疗需要寻找替代预处理淋巴清除方案。本文报告一例复发/难治性B细胞急性淋巴细胞白血病患者，接受多线挽救治疗后仍有广泛病灶，输注tisagenlecleucel CD19 CAR-T 前以克拉屈滨和环磷酰胺进行淋巴清除，最终获得缓解。该病例提供了克拉屈滨联合tisagenlecleucel治疗B-ALL的活性证据。患者出现CRS，最终流式细胞术和下一代测序均显示MRD阴性，支持克拉屈滨未削弱CAR-T 疗效。
展开英文摘要原文
Given the shortage of fludarabine, alternative preparative lymphodepleting regimens for CAR-T-cell therapy need to be identified.
We present a case of relapsed/refractory B-cell acute lymphoblastic leukemia requiring multiple lines of salvage therapy with persistent extensive disease, who underwent lymphodepletion with clofarabine and cyclophosphamide before tisagenlecleucel CD19+ CAR-T-cell infusion with eventual remission.
We offer evidence of clofarabine's activity against B-cell acute lymphoblastic leukemia in combination with tisagenlecleucel therapy. In this patient, clofarabine did not decrease CAR-T-cell effectiveness, supported by presence of cytokine release syndrome and ultimate minimal residual disease negativity both on flow cytometry and next-generation sequencing.
论文信息
- 作者
- Foti A、Stein D、Seidel D、Levine J、Hijiya N、Williams O、George D、Bhatia M
- 单位
- Division of Pediatric Hematology/Oncology/Stem Cell Transplantation, Department of Pediatrics, Columbia University Irving Medical Center.
- 文献类型
- 病例报告
- 期刊
- Journal of pediatric hematology/oncology2023 May 1
- 原文标识
- PubMed 37027246 · DOI 10.1097/MPH.0000000000002668